

Lightning Talks Session I

Tuesday, January 20, 2026, from 7:30 to 9:30 p.m.

Docetaxel and the Tumor Targeting Interleukin-12 (IL-12) PDS01ADC in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)*

Melissa Lauren Abel

National Institute of Health, Bethesda, MD

A dependency map of androgen receptor activity identifies drivers of prostate cancer growth*

Arnab Bose

Fred Hutchinson Cancer Center, Seattle, WA

High-dimensional spatial profiling identifies distinct and targetable tumor-infiltrating lymphocyte phenotypes in localized prostate cancer*

Precious Cramer

Beth Israel Deaconess Medical Center, Boston, MA

Spatial Mapping of Accessible Chromatin Landscapes in Prostate Cancer*

Leigh Ellis

Center for Prostate Disease Research, Bethesda, MD

Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity*

Sanjana Eyunni

University of Michigan, Ann Arbor, MI

Comprehensive spatial profiling of prostate cancer metastasis: Mapping clonal evolution, microenvironment dynamics, and early metastatic markers*

Mengxiao He

Science for Life Laboratory, Solna, Sweden

PARP Inhibition Beyond BRCA in Prostate Cancer: The Roles of MMS22L and NDUFAF4*

Li Jia

Brigham and Women's Hospital/Harvard Medical School, Boston, MA

Super-enhancer landscape analysis reveals a HOXB13-HNF1A transcriptional axis driving hepatic reprogramming in castration-resistant prostate cancer*

Mingyu Liu

University of Massachusetts, Boston, MA

The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer*

Kent Nastiuk

Roswell Park, Buffalo, NY

Dissecting the role of CHD1 as a key regulator of pro-metastatic transcriptional reprogramming in BRCA2-mutant prostate cancer

Jingzhu Hao

University of Massachusetts, Boston, MA

Enhancing androgen receptor antagonist-mediated interferon responses in prostate cancer*

Larysa Poluben

Beth Israel Deaconess Medical Center, Boston, MA

Combining CBP/p300 and PARP inhibitors to enhance anti-tumor efficacy in lethal prostate cancer*

Orly I. Richter

National Cancer Institute, Bethesda, MD

Targeting of FOXA1 and FOXA2 by small molecules disables the oncogenic output of castration resistant prostate cancer*

Jean-Philippe Paul Theurillat

Institute of Oncology Research, Bellinzona, Switzerland

A cancer vaccine for de novo metastatic prostate cancer: learning patients stratification from the UV1 trial*

Alfonso Urbanucci

Oslo University Hospital, Oslo, Norway

Polycomb dysregulation shapes chromatin bivalency critical for prostate cancer lineage plasticity*

Varadha Balaji Venkadakrishnan

Dana-Farber Cancer Institute, Boston, MA

Development of a fully humanized vascularized "tumor on a chip" model for prostate cancer liver metastasis*

Katherine Vietor

University of Wisconsin-Madison, Madison, WI

Circulating tumor DNA methylation captures epigenetic changes in patients induced by the PRC2 inhibitor ORIC-944*

Amber W. Wang

ORIC Pharmaceuticals, South San Francisco, CA

Mosaic loss of Y chromosome and risk of prostate cancer in two U.S. cohorts*

Anqi Wang

Harvard T. H. Chan School of Public Health, Boston, MA

A bypass gateway from cholesterol to sex steroid biosynthesis circumnavigates CYP17A1*

Ziqi Zhu

University of Miami, FL